EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

ANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

Yong Luo iD, Tianlong Luo, Lingfeng Li, Qi Sun, Dongquan Li, Shanhe Huang, Zonglin Li, Weilong Lin iD, Yuan Ou, Tao Du, Shengmeng Peng iD, Kewei Xu iD and 2 more

Advanced Science · 2026

DOI: 10.1002/advs.75290 ↗

At a glance

Journal article in Advanced Science, 2026. Written by Yong Luo and 13 co-authors. Institution: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Major MEDLINE topics: Nitriles, Phenylthiohydantoin, Phagocytosis, Benzamides. Cited 1 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Guangdong Provincial Science and Technology Program, National Natural Science Foundation of China, National key R&D plan of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Resistance to second‐generation antiandrogens like enzalutamide (ENZ) in castration‐resistant prostate cancer (CRPC) is a major clinical challenge, yet the role in the tumor microenvironment remains poorly understood. This study identifies a unique AR‐positive tumor‐associated macrophages (AR + TAMs) subpopulation, enriched in ENZ‐resistant patients and correlated with poor prognosis, which acquires functional AR protein not through endogenous expression but via ANXA2‐dependent phagocytosis of tumor cells. The internalized AR protein translocates to the macrophage nucleus, directly binds the IL‐6 promoter to enhance its transcription and secretion. Macrophage‐derived IL‐6 subsequently activates the JAK2/STAT3 pathway in cancer cells, suppressing ENZ‐induced apoptosis and conferring therapeutic resistance. Genetic or pharmacological blockade of IL‐6 signaling restored ENZ sensitivity in vitro and in vivo, and combining an anti‐IL‐6 antibody with ENZ synergistically overcomes resistance in patient‐derived xenograft and orthotopic models. These findings reveal a novel phagocytosis‐mediated, paracrine mechanism of ENZ resistance orchestrated by AR + TAMs, challenging the tumor‐centric view of therapy failure and providing a strong rationale for co‐targeting the IL‐6 pathway to improve outcomes of AR‐directed therapy in CRPC.

Subjects

MeSH terms (MEDLINE)

NitrilesPhenylthiohydantoinPhagocytosisBenzamidesDrug Resistance, NeoplasmMacrophagesProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTumor-Associated MacrophagesMaleHumansAnimalsMiceInterleukin-6Cell Line, TumorTumor MicroenvironmentSignal Transduction

Author keywords

AR+ TAMsCRPCIL‐6 signalingenzalutamide resistancephagocytosis

Substances

NitrilesenzalutamidePhenylthiohydantoinBenzamidesInterleukin-6Receptors, Androgen

Authors and institutions

  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Obstetrics and Gynecology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.

ORCID profiles: Yong Luo, Weilong Lin, Shengmeng Peng, Kewei Xu, Bisheng Cheng, Hai Huang

Funding

  • Guangdong Provincial Science and Technology Program
  • National Natural Science Foundation of China
  • National key R&D plan of China
  • International Science and technology cooperation project plan of Guangdong Province
  • Sun Yat-Sen University Clinical Research 5010 Program
  • Beijing Bethune Charitable Foundation
  • Guangzhou Science and Technology Key R&D Project
  • Beijing Xisike Clinical Oncology Research Foundation

Cite

APA

Luo, Y., Luo, T., Li, L., Sun, Q., Li, D., Huang, S., Li, Z., Lin, W., Ou, Y., Du, T., Peng, S., Xu, K., Cheng, B., & Huang, H. (2026). ANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer. Advanced Science. https://doi.org/10.1002/advs.75290

Vancouver

Luo Y, Luo T, Li L, Sun Q, Li D, Huang S, et al. ANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer. Advanced Science. 2026. doi:10.1002/advs.75290

BibTeX
@article{Luo2026,
  author = {Luo, Yong and Luo, Tianlong and Li, Lingfeng and Sun, Qi and Li, Dongquan and Huang, Shanhe and Li, Zonglin and Lin, Weilong and Ou, Yuan and Du, Tao and Peng, Shengmeng and Xu, Kewei and Cheng, Bisheng and Huang, Hai},
  title = {ANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.75290}
}
Start for free →